Breaking News Instant updates and real-time market news.

DRRX

Durect

$1.31

0.01 (0.77%)

, NVS

Novartis

$80.83

0.38 (0.47%)

07:03
06/19/17
06/19
07:03
06/19/17
07:03

Durect collaboration with Sandoz clears HSR review, now effective

DURECT (DRRX) announced that the previously disclosed development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States DURECT's POSIMIR, an investigational locally acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery, has cleared review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and has become effective. Under the terms of the agreement, Sandoz has made an upfront payment to DURECT of $20M, with the potential for up to an additional $43M in development and regulatory milestones, up to an additional $230M in sales-based milestones, as well as a tiered double-digit royalty on product sales in the United States. DURECT remains responsible for the completion of the ongoing PERSIST Phase 3 clinical trial for POSIMIR as well as FDA interactions through approval.

DRRX

Durect

$1.31

0.01 (0.77%)

NVS

Novartis

$80.83

0.38 (0.47%)

  • 26

    Jun

DRRX Durect
$1.31

0.01 (0.77%)

02/28/17
HCWC
02/28/17
INITIATION
Target $3
HCWC
Buy
Durect assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce assumed coverage of Durect with a Buy rating and $3 price target.
NVS Novartis
$80.83

0.38 (0.47%)

06/01/17
NEED
06/01/17
NO CHANGE
Target $4.5
NEED
Buy
Cryoport price target raised to $4.50 from $3.50 at Needham
Needham analyst Sean Hannan noted that Novartis (NVS) and Kite Pharma (KITE) both have Biologics License Applications nearing approval for studies believed to be supported by Cryoport (CYRX). Citing his growing comfort on clients' progress toward commercialization, he raised his price target on Cryoport to $4.50 from $3.50 and keeps a Buy rating on the "arms provider" to companies working on emerging regenerative therapies.
06/06/17
LEER
06/06/17
NO CHANGE
Target $100
LEER
Outperform
bluebird data among most impressive in CAR-T space, says Leerink
Leerink analyst Michael Schmidt says bluebird bio's (BLUE) bb2121 dose-escalation data in multiple myeloma is among the most impressive early data sets he's seen in the CAR-T space to date. The data sets a high bar for the competition, which includes Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS), Schmidt tells investors in a research note. Being one year ahead of the competition provides bluebird and Celgene (CELG) with an ideal position in multiple myeloma, the analyst adds. He keeps an Outperform rating on bluebird shares with a $100 price target.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/08/17
06/08/17
UPGRADE
Target $100

Buy
Kite Pharma upgraded to Buy on Axi-Cel manufacturing edge at BTIG
As previously reported, BTIG analyst Dane Leone upgraded Kite Pharma (KITE) to Buy from Neutral and set a $100 price target on the shares. Data from Novartis (NVS) and Juno (JUNO) have failed to deliver any recognizable differentiation, though Leone gives Kite "a clear win" for the manufacturing of Axi-Cel versus peers, he tells investors. The analyst sees Kite having the cleanest pathway to approval for diffuse large B-cell lymphoma and, given Kite's manufacturing edge, he estimates that Axi-Cel can take about 60% of share within the U.S. DLBCL market.

TODAY'S FREE FLY STORIES

JEC

Jacobs Engineering

$56.76

0.81 (1.45%)

, AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

07:46
09/19/17
09/19
07:46
09/19/17
07:46
Hot Stocks
Jacobs Engineering selected by Aerie Pharmaceuticals as engineering contractor »

Jacobs Engineering Group…

JEC

Jacobs Engineering

$56.76

0.81 (1.45%)

AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

  • 28

    Feb

BNPQY

BNP Paribas

$39.68

0.19 (0.48%)

, AXAHY

AXA

$29.47

0.13 (0.44%)

07:46
09/19/17
09/19
07:46
09/19/17
07:46
Periodicals
BNP weighing tie-up of money-management division with Axa unit, Bloomberg says »

BNP Paribas (BNPQY),…

BNPQY

BNP Paribas

$39.68

0.19 (0.48%)

AXAHY

AXA

$29.47

0.13 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHFC

Chemical Financial

$49.32

0.71 (1.46%)

07:45
09/19/17
09/19
07:45
09/19/17
07:45
Downgrade
Chemical Financial rating change  »

Chemical Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSII

Quality Systems

$15.71

-0.14 (-0.88%)

07:45
09/19/17
09/19
07:45
09/19/17
07:45
Initiation
Quality Systems initiated  »

Quality Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:45
09/19/17
09/19
07:45
09/19/17
07:45
General news
N.Y. FX Outlook »

N.Y. FX Outlook: Risk-on…

HOLI

Hollysys

$20.77

0.42 (2.06%)

07:44
09/19/17
09/19
07:44
09/19/17
07:44
Conference/Events
Hollysys management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 16

    Oct

CYTK

Cytokinetics

$14.25

0.1 (0.71%)

, AMGN

Amgen

$186.47

-1 (-0.53%)

07:44
09/19/17
09/19
07:44
09/19/17
07:44
Hot Stocks
Cytokinetics doses first patient in Japan in GALACTIC-HF Phase 3 trial »

Cytokinetics announced…

CYTK

Cytokinetics

$14.25

0.1 (0.71%)

AMGN

Amgen

$186.47

-1 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

KORS

Michael Kors

$44.65

-0.27 (-0.60%)

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Technical Analysis
Technical View: Michael Kors moves higher, analyst action »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Periodicals
Intel Capital invested over $1B in AI-focused companies, TechCrunch says »

Intel has invested more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 05

    Oct

PDCO

Patterson Companies

$37.94

-0.59 (-1.53%)

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Initiation
Patterson Companies initiated  »

Patterson Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$179.98

3.28 (1.86%)

, BSTI

BEST Inc

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Syndicate
BEST Inc cuts size of proposed IPO following 'tepid' response, Reuters reports »

Best Inc (BSTI), a…

BABA

Alibaba

$179.98

3.28 (1.86%)

BSTI

BEST Inc

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FOLD

Amicus

$13.67

-0.21 (-1.51%)

07:42
09/19/17
09/19
07:42
09/19/17
07:42
Hot Stocks
Amicus granted FDA Fast Track Designation for migalastat »

Amicus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$2.73

0.1 (3.80%)

07:41
09/19/17
09/19
07:41
09/19/17
07:41
Initiation
Rite Aid initiated  »

Rite Aid initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MDGL

Madrigal Pharmaceuticals

$19.80

0.99 (5.26%)

07:41
09/19/17
09/19
07:41
09/19/17
07:41
Hot Stocks
Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB review »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MDSO

Medidata

$75.85

-0.01 (-0.01%)

07:40
09/19/17
09/19
07:40
09/19/17
07:40
Initiation
Medidata initiated  »

Medidata initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ABX

Barrick Gold

$16.92

-0.38 (-2.20%)

07:40
09/19/17
09/19
07:40
09/19/17
07:40
Conference/Events
Barrick Gold management to meet with Deutsche Bank »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 26

    Oct

07:40
09/19/17
09/19
07:40
09/19/17
07:40
General news
Treasury Market Outlook: yields are a little lower »

Treasury Market Outlook:…

SFTBF

SoftBank

$78.30

0.3501 (0.45%)

07:39
09/19/17
09/19
07:39
09/19/17
07:39
Periodicals
SoftBank Ventures Korea looks to invest in promising start-ups, CNBC says »

SoftBank Ventures Korea,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$148.42

-1.46 (-0.97%)

07:38
09/19/17
09/19
07:38
09/19/17
07:38
Initiation
McKesson initiated  »

McKesson initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

SUPN

Supernus

$49.65

0.6 (1.22%)

07:37
09/19/17
09/19
07:37
09/19/17
07:37
Downgrade
Supernus rating change  »

Supernus downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

HSIC

Henry Schein

$80.90

-1.98 (-2.39%)

07:37
09/19/17
09/19
07:37
09/19/17
07:37
Initiation
Henry Schein initiated  »

Henry Schein initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMX

CarMax

$68.34

0.26 (0.38%)

07:36
09/19/17
09/19
07:36
09/19/17
07:36
Recommendations
CarMax analyst commentary  »

CarMax price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

PTLA

Portola Pharmaceuticals

$56.57

1.62 (2.95%)

07:36
09/19/17
09/19
07:36
09/19/17
07:36
Periodicals
Portola blood thinner launch could be complicated by guidelines, STAT News says »

The commercial launch of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

CRL

Charles River

$107.29

1.27 (1.20%)

07:35
09/19/17
09/19
07:35
09/19/17
07:35
Initiation
Charles River initiated  »

Charles River initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$85.84

1.04 (1.23%)

, BOBE

Bob Evans

$72.93

1.02 (1.42%)

07:35
09/19/17
09/19
07:35
09/19/17
07:35
Hot Stocks
Post Holdings to acquire Bob Evans for $77.00 per share »

Post Holdings (POST) and…

POST

Post Holdings

$85.84

1.04 (1.23%)

BOBE

Bob Evans

$72.93

1.02 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.